ArticleBMC pulmonary medicine2025
Evaluation of the impact of pulmonary circulation, particularly pulmonary vascular resistance, in patients with idiopathic pulmonary fibrosis: an exploratory study.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a progressive disease often complicated by pulmonary hypertension (PH), leading to a worse prognosis. In this study, we use the term “secondary PH” to refer to PH that develops as a complication of IPF (i.e., IPF-PH), and “the ERPE (Exercise-Responsive PAP Elevation) group, defined as patients without resting PH but with potential PAP elevation during exertion, indicating early pulmonary vascular stress.” This study aimed to evaluate the impact of pulmonary vascular resistance (PVR) on the clinical course, activities of daily living (ADL), and exercise tolerance in IPF patients. Additionally, we sought to determine whether PVR influences prognosis within a short-term period of just two years.
methodsThis exploratory single-center study was conducted as an interim analysis of a prospective trial targeting patients with IPF complicated by secondary PH or ERPE. The analysis included 49 IPF patients who received conventional IPF management without pulmonary arterial hypertension (PAH)-specific therapies and completed a two-year follow-up. Pulmonary circulation parameters, including PVR and pulmonary artery pressure (PAP), were assessed via right heart catheterization. Lung function, ADL, and exercise tolerance were also evaluated. Statistical analyses were performed to assess the association between PVR and prognosis.
resultsHigher PVR was significantly associated with poorer prognosis and worsening restrictive lung impairment. PVR correlated with modified Medical Research Council (mMRC) scores (Spearman’s ρ = 0.47, p = 0.0007) and 6-minute walk distance (Spearman’s ρ = -0.41, p = 0.0042). Proportional hazard analysis identified PVR as a significant predictor of overall survival (hazard ratio [HR]: 1.28, 95% confidence interval [CI]: 1.0055–1.53, p = 0.013). PVR also strongly correlated with maximum exercise tolerance (Spearman’s ρ = -0.60, p < 0.0001). Importantly, even within the short two-year follow-up, elevated PVR significantly impacted both home-stay survival (HR: 1.20, 95% CI: 1.0072–1.41, p = 0.032) and overall survival, underscoring its predictive value over a short time frame.
conclusionsPVR is associated with prognosis, ADL, and exercise tolerance in IPF patients. Importantly, even within a short two-year period, PVR was significantly linked to clinical outcomes. While causality cannot be established, our findings suggest that PVR may serve as a potentially useful early prognostic marker. Regular PVR monitoring could provide valuable insights into disease progression and may support earlier therapeutic interventions to improve outcomes.
trial registrationThis study is registered in the UMIN Clinical Trials Registry (UMIN000055468). Trial registration at 10/09/2024. Retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.